CY1114479T1 - Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος - Google Patents

Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος

Info

Publication number
CY1114479T1
CY1114479T1 CY20131100809T CY131100809T CY1114479T1 CY 1114479 T1 CY1114479 T1 CY 1114479T1 CY 20131100809 T CY20131100809 T CY 20131100809T CY 131100809 T CY131100809 T CY 131100809T CY 1114479 T1 CY1114479 T1 CY 1114479T1
Authority
CY
Cyprus
Prior art keywords
pharmacological
introduction
combination
surgery
tgf
Prior art date
Application number
CY20131100809T
Other languages
English (en)
Inventor
Stephen P Bartels
Original Assignee
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Incorporated filed Critical Bausch & Lomb Incorporated
Publication of CY1114479T1 publication Critical patent/CY1114479T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Σύνθεση για έλεγχο ή αποτροπή εξέλιξης γλαυκώματος περιλαμβάνει υλικό που μειώνει ή αναστέλλει την παραγωγή ισόμορφης ΤGF-β ή χημειοκίνης ή κυτοκίνης που διεγείρει την έκφραση ισόμορφης ΤGF-β. Το υλικό μπορεί να περιλαμβάνει διαχωρισμένο αγωνιστή υποδοχέα γλυκοκορτικοειδούς (“DIGRA”: dissociated glucocorticoid receptor agonist), προφάρμακο αυτού, φαρμακευτικά αποδεκτό άλας αυτού, ή φαρμακευτικά αποδεκτό εστέρα αυτού. Η σύνθεση μπορεί επιπλέον να περιλαμβάνει ανταγωνιστή του ΤGF-β. Χορηγείται σε ασθενή που έχει υποβληθεί σε διηθητική χειρουργική επέμβαση γλαυκώματος για να εξασφαλίσει λειτουργική διηθητική φυσαλίδα μετά από τέτοια χειρουργική επέμβαση.
CY20131100809T 2007-09-27 2013-09-18 Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος CY1114479T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97562007P 2007-09-27 2007-09-27
EP08799307.7A EP2203160B1 (en) 2007-09-27 2008-09-08 Pharmacological adjunctive treatment associated with glaucoma filtration surgery

Publications (1)

Publication Number Publication Date
CY1114479T1 true CY1114479T1 (el) 2016-10-05

Family

ID=40043043

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100809T CY1114479T1 (el) 2007-09-27 2013-09-18 Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος

Country Status (19)

Country Link
US (1) US20090087443A1 (el)
EP (1) EP2203160B1 (el)
JP (1) JP5249336B2 (el)
KR (1) KR20100065166A (el)
CN (1) CN101878026B (el)
AU (1) AU2008305407B2 (el)
BR (1) BRPI0817472A2 (el)
CA (1) CA2699599C (el)
CY (1) CY1114479T1 (el)
DK (1) DK2203160T3 (el)
ES (1) ES2424008T3 (el)
HK (1) HK1145014A1 (el)
HR (1) HRP20130817T1 (el)
MX (1) MX2010003198A (el)
PL (1) PL2203160T3 (el)
PT (1) PT2203160E (el)
SI (1) SI2203160T1 (el)
TW (1) TWI366462B (el)
WO (1) WO2009042377A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045463A2 (en) * 2008-10-15 2010-04-22 Government Of The United States As Represented By The Secretary Of The Army Clinical decision model
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US10189773B2 (en) 2010-05-07 2019-01-29 Medicus Biosciences, Llc In-vivo gelling pharmaceutical pre-formulation
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10111985B2 (en) * 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
CA2873105C (en) 2012-05-11 2018-01-16 Medicus Biosciences, Llc Biocompatible hydrogel treatments for retinal detachment
EA201891724A1 (ru) * 2016-02-17 2019-01-31 Новартис Аг Антитела к tgf-бета2
US12027276B1 (en) 2017-10-27 2024-07-02 DecisionQ Corporation Methods, systems and devices for assessing wound healing
EP3914249B1 (en) 2019-01-22 2024-05-01 Akribes Biomedical GmbH Selective glucocorticoid receptor modifiers for treating impaired skin wound healing

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
AU760562B2 (en) * 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
CA2472746A1 (en) * 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
ES2298508T3 (es) * 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
EP1490317A1 (en) * 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003297363A1 (en) * 2002-12-23 2004-07-22 Alcon, Inc. Use of cathepsin k inhibitors for the treatment of glaucoma
CA2512257A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
JP2007530541A (ja) * 2004-03-22 2007-11-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン
US20050230128A1 (en) * 2004-04-06 2005-10-20 Smith Bret A Replaceable trench blade
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
SI2056799T1 (sl) * 2006-08-31 2013-11-29 Bausch & Lomb Incorporated Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja
ATE506061T1 (de) * 2006-09-11 2011-05-15 Bausch & Lomb Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien

Also Published As

Publication number Publication date
HRP20130817T1 (hr) 2013-09-30
DK2203160T3 (da) 2013-09-02
JP2010540538A (ja) 2010-12-24
MX2010003198A (es) 2010-04-01
CA2699599C (en) 2012-10-23
EP2203160A1 (en) 2010-07-07
WO2009042377A1 (en) 2009-04-02
ES2424008T3 (es) 2013-09-26
CA2699599A1 (en) 2009-04-02
CN101878026A (zh) 2010-11-03
HK1145014A1 (en) 2011-03-25
AU2008305407B2 (en) 2012-12-20
BRPI0817472A2 (pt) 2015-03-24
EP2203160B1 (en) 2013-07-17
PL2203160T3 (pl) 2013-11-29
SI2203160T1 (sl) 2013-11-29
JP5249336B2 (ja) 2013-07-31
PT2203160E (pt) 2013-10-22
CN101878026B (zh) 2013-11-20
AU2008305407A1 (en) 2009-04-02
US20090087443A1 (en) 2009-04-02
TWI366462B (en) 2012-06-21
TW200914014A (en) 2009-04-01
KR20100065166A (ko) 2010-06-15

Similar Documents

Publication Publication Date Title
CY1114479T1 (el) Φαρμακολογικη επικουρικη αγωγη σε συνδυασμο με διηθητικη χειρουργικη επεμβαση γλαυκωματος
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
BR0315315A (pt) Método para tratar, prevenir ou controlar uma sìndrome mielodisplásica, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
PH12021551196A1 (en) 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
TW200603787A (en) Topical preparations containing ambroxol
CY1114263T1 (el) Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
AR069349A1 (es) Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular
MX2010002781A (es) Combinacion novedosa de angentes terapeuticos.
CO2021006482A2 (es) Ureas cíclicas
MX2010003923A (es) Formulacion farmaceutica de valsartan.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
CY1109939T1 (el) Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου